PTK2 and neoplasm: To assess the translational value of combining FAK and FGFR inhibitors in PDAC treatment, we examined the effect of the FAK inhibitor VS-6063 (Defactinib) on the growth of tumor cells in vitro and in vivo, in combination with Erdafitinib, a pan-FGFR inhibitor.